CSL-Ltd-CSLAX-Deep-dive-into-Pipeline-A12-to-Target-Price.pdf
This is a recently released Goldman Sachs report detailing the current R&D landscape for CSL. It provides the rational behind their $312 target price. Of course, with all broker reports you have to take them with a grain of salt. However, they explore each of the 15 projects in/near active development, assessing the data and the likely regulatory pathway and financial impact. Awesome read for anyone wanted a breakdown of the underlying molecules, the target markets and the overall opportunities. I feel sorry for the intern Riashad Monjur, who gets a brief shoutout for probably writing the whole thing. As usual DYOR.
Goldman Sachs R&D Report
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$288.80 |
Change
-0.300(0.10%) |
Mkt cap ! $139.5B | |||
| Open | High | Low | Value | Volume |
| $288.06 | $290.40 | $287.86 | $189.1M | 654.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $288.75 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $288.81 | 1380 | 2 |
View Market Depth
| Last trade - 16.10pm 17/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$288.01 |
Change
-0.300 ( 0.37 %) |
||||
| Open | High | Low | Volume | ||
| $288.40 | $290.39 | $287.66 | 103444 | ||
| Last updated 15.59pm 17/06/2024 ? | |||||
| CSL (ASX) Chart |
